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Introduction: Little is known about the risk of cancer in patients with chronic obstructive
pulmonary disease (COPD), including which cancer sites are most affected. We examined
the short- and long-term risk of lung and extrapulmonary cancer in a nationwide cohort of
COPD patients.
Methods: We linked the Danish National Registry of Patients and the nationwide cancer
registry, and examined the incidence of various cancers in 236,494 individuals with a first inci-
dent hospital contact with COPD during 1980e2008. The observed cancer incidence in this
cohort was compared with the expected incidence in the general population on the basis of
national age-, sex-, and site-specific incidence rates.
Results: Median follow-up was 3.5 years. During the first year of follow-up, 9434 cancers were
diagnosed in COPD patients [standardized incidence ratio (SIR)Z 3.1; 95% CI 3.0 to 3.2]. The 1-
year SIR was 8.5 (8.2e8.9) for lung cancer, 5.1 (5.0e5.2) for all tobacco-related cancers, and
1.9 (1.9e2.0) for other cancers. In the following years, cancer incidence was increased 1.4-
fold (1.4e1.5) in COPD patients. These patients had an increased risk of developing
tobacco-related cancers (SIR Z 2.1; 95% CI 2.0e2.1), including cancers of the lung, larynx,
tongue, oral cavity, pharynx, esophagus, stomach, liver, pancreas, cervix uteri, and urinary
tract (with SIRs ranging between 1.3 and 2.8).ity Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DCR, Danish Cancer
try of Patients; SIR, Standardized incidence ratio.
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846 J.B. Kornum et al.Conclusions: Patients with first-time hospital-diagnosed COPD are at considerably increased
risk of developing both lung cancer and extrapulmonary cancers. Physicians should be aware
of cancer in COPD patients.
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Chronic obstructive pulmonary disease (COPD) is currently
the fourth most frequent cause of death in the world and
a major cause of hospitalizations.1,2 In Europe and North
America, the prevalence of COPD is at least 10% among
adults aged 40 years and older.3e6 The prevalence is
increasing, due to population aging and a decline in all-
cause mortality.5
It has been known for many decades that COPD and lung
cancer often occur together.7e9 There is evidence that the
risk of developing lung cancer is substantially increased in
individuals with COPD and may be associated with the
severity of lung function impairment and with chronic mucus
hypersecretion.10e14 Given the systemic inflammation
accompanying COPD and shared risk factors formany cancers
(e.g., smoking), it is also plausible that COPD is associated
with an increased risk of extrapulmonary cancers.15e17
Available evidence for such association is limited. In
a Dutch cohort study, COPD was linked with 1.4-fold
increased mortality from extrapulmonary cancers.15 In
a Swedish study of male construction workers, those with
moderate or severe COPD had a 1.6-fold [95% confidence
interval (CI) 1.4 to 2.0] increased risk of any extrapulmonary
tobacco-related cancer.12 A Japanese cohort study including
127 COPD patients found a 2.3-fold (1.2e4.3) greater risk of
developing any cancer as compared with patients with
“benign respiratory disease”.18 To our knowledgenoprevious
large-scale studies have examined themagnitude and period
of increased risk of specific cancer sites associated with
COPD, or addressed the impact of comorbidity on cancer risk.
Data on these topics could provide insight into the clinical
course of patients with COPD and may have implications for
the clinical follow-up of this large patient group, potentially
including surveillance for cancer. We therefore examined
short- and long-term cancer risk by site after a first hospital
contact with COPD in Denmark, using data from the Danish
Cancer Registry and a nationwide hospital registry.
Materials and methods
The Danish healthcare system provides tax-supported
healthcare services to all residents, guaranteeing free
access to hospitals and primary medical care. The civil
registration number, a unique identifier assigned to every
Danish citizen, allowed for accurate linkage among the
databases used in this study.19
Identification of patients with COPD
We used the Danish National Registry of Patients (DNRP),
covering all Danish hospitals,20 to identify all patients aged40 years or older with COPD, defined by a first-time inpa-
tient hospitalization or hospital outpatient clinic or emer-
gency room visit with a diagnosis of COPD (ICD-8 codes:
491e492; ICD-10 codes: J41-J44) between 1980 and 2008.21
Data on comorbidity and alcoholism-related
conditions
For supplemental analyses, we retrieved data on comor-
bidities included in the Charlson Comorbidity Index, iden-
tified as conditions recorded in the DNRP before each
patient’s first hospital contact with COPD22: previous
myocardial infarction, congestive heart failure, peripheral
vascular disease, cerebrovascular disease, dementia,
chronic pulmonary disease, connective tissue disease,
peptic ulcer disease, liver disease, diabetes mellitus,
hemiplegia, renal disease, any solid malignancy, leukemia,
lymphoma, metastatic cancer, and AIDS. Three comorbidity
levels were defined: low (score of 0), medium (score of
1e2), and high (score of 3). We also identified persons
with a history of alcoholism-related conditions not included
in the CCI, by retrieving ICD codes for any mental or
behavioural disorders due to alcohol use (including acute
intoxication, dependence, psychotic or amnestic disor-
ders), and codes for alcoholic organ damage other than
liver disease (including alcohol-related neuropathy, myop-
athy, cardiomyopathy, gastritis, and pancreatitis).21
Identification of cancer
We obtained information on all cancer diagnoses (except
non-melanoma skin cancers) from theDanishCancer Registry
(DCR). The DCR stores data on cancer incidence in entire
Denmark and is 95%e98% complete and valid.23 We excluded
patients with a cancer diagnosis other than non-melanoma
skin cancer preceding the first hospital contact with COPD.
Statistical analysis
We followed COPD patients to detect any occurrence of
cancer from the date of first hospital contact with COPD
until the date of death, emigration, or Dec 31, 2008,
whichever came first.
The standardized incidence ratio (SIR) of cancer was
computed as the observed number of cancers divided by the
expected number of cancers. The expected number was
obtained bymultiplying the number of person-years at risk in
our cohort by national cancer incidence rates according to
sex, age, and year of diagnosis in 5-year intervals.24 Because
a hospital contact with COPDmay be related to undiagnosed
pulmonary and other cancer, we computed SIRs separately
for early (first year) and longer-term (subsequent years)
COPD and cancer risk 847follow-up. SIRs with 95% CIs assuming a Poisson distribution
were computed for any cancer, for site-specific cancers, and
for the following malignancy subgroups: tobacco-related
cancers,25 non-tobacco-related cancers, alcohol-related
cancers,26 cancers associated with immunosuppression,27
and hematological cancers (for ICD-10 codes see Tables
1e4 in the Results section).
The SIR for cancer was computed separately for inpatient
or outpatient diagnoses of COPD, and stratified by sex and
age group (40e49, 50e69, and 70 þ years) and by calendar
time periods. We also computed SIRs for cancer separately
for COPD patients with and without an alcoholism-related
condition and for COPD patients with different levels of CCI
scores. Finally, to summarize time-to-events, we calculated
the cumulative incidence of cancer, treating death as
a competing risk. We used SAS software (version 9.2, SAS
Institute, Cary, NC). The Danish Registry Board approved the
study. According to Danish law, this purely registry-based
project needed no further IRB approval.
Results
We identified 236,494 patients (107,150 women and
129,344 men) with a first hospital contact with COPD
between 1980 and 2008 (Table 1). The median age was 70
years (range 40e90 years) and median follow-up time was
3.5 years (IQR: 1.1e7.3 years).
Any cancer
COPD patients had a substantially higher risk of cancer than
persons in the general population. In the first year of
follow-up, 9434 cancers were identified among COPD
patients, yielding an SIR for any cancer of 3.1 (95% CI
3.0e3.2) (Table 1). This result was similar for men and
women. Individuals aged 70 years or older had the lowest
relative risk of cancer in the first year of follow-up
(SIR Z 2.7; 95% CI 2.6e2.8), while 1-year relative risks
were elevated approximately fourfold among those aged
40e69 years. One-year SIRs decreased from 3.9 to 2.6
between 1980 and 1999, and then rose slightly to 2.9 in
2005e2008. The relative risk for cancer during the first year
was lower among COPD patients whose first hospital
contact was as an outpatient (SIR Z 2.4; 95% CI 2.3e2.5).
Presence of an alcoholism-related diagnosis increased the
relative cancer risk (SIR Z 3.9; 95% CI 3.6e4.2) (Table 2),
while the overall level of comorbidity had little influence
on relative risk (Table 3).
After the first year of follow-up, 22,759 cancers were
diagnosed in the COPD cohort (SIR Z 1.4; 95% CI 1.4e1.5)
(Table 1). COPD patients aged less than 70 years continued
to have higher relative risk increase for cancer than elderly
COPD patients. The longer-term cancer SIRs remained
stable at 1.4e1.5 in each calendar period examined, and
were similar regardless of inpatient or outpatient COPD
status (Table 1) or level of comorbidity (Table 3). The SIR
was 2.1 (2.0e2.2) among COPD patients who also had an
alcoholism-related diagnosis (Table 2). Fig. 1 summarizes
overall cancer risk by length of follow-up time. After the
first year of follow-up, the SIRs remained rather stable yet
with a slight decline over the next nine years.Tobacco-related cancers
In the first year of follow-up, the SIR for tobacco-related
cancer in COPD patients was 5.1 (5.0e5.2) (Table S1, see
online data supplement). During that period, we found
a particularly high risk for cancers of the lung, bronchus,
and trachea (SIRZ 8.5; 95% CI 8.2e8.8). SIRs were also 2 or
greater for most other tobacco-related cancers, including
cancers of the oral cavity, esophagus, stomach, liver,
pancreas, larynx, kidney, renal pelvis, urinary bladder, and
myeloid leukemia (Table S1).
After the first year of follow-up, the SIR for tobacco-
related cancer was 2.1 (2.0e2.1) (Table S2, see online data
supplement). Patients had a substantially raised risk of
cancers of the lung, bronchus, and trachea (SIRZ 2.8; 95%
CI: 2.7e2.8), but we also found elevated SIRs (1.3 or higher)
for cancers of the tongue, oral cavity, pharynx, esophagus,
stomach, liver, pancreas, larynx, cervix uteri, and urinary
tract (Table S2). The relative risk for cancers of the lung,
bronchus, and trachea remained elevated after more than
10 years of follow-up (SIR Z 2.5; 95% CI: 2.3e2.6).
The cumulative risk for lung cancer in the COPD cohort
after 1, 5 and 10 years was 1.8% (1.7%e1.9%), 3.6% (95% CI
3.6%e3.7%) and 4.9% (4.9%e5.0), respectively (Table 4).
The corresponding risks for other tobacco-related cancers
were 0.6% (0.6%e0.7%), 1.8% (1.8%e1.9%) and 2.7% (2.6%e
2.8%). For any cancer, the 10-year incidence reached
14.2%.
Alcohol-related cancers
The SIR for alcohol-related cancers was 1.7 (1.6e1.8) in the
first year of follow-up (Table S1) and 1.2 (1.1e1.2) in
subsequent years (Table S2). In the later period, SIRs were
elevated mainly for cancers that were also classified as
tobacco-related cancers (cancers of the oral cavity,
pharynx, esophagus, larynx, and liver). The 10-year inci-
dence of alcohol-related cancers was 3.2% (3.1%e3.2%)
(Table 4).
Immune-related and hematological cancers
In the first year of follow-up, the SIR for immune-related
cancers was 1.9 (1.7e2.1), while the SIR for hematological
cancers was 2.7 (2.5e2.9). We found a particularly high risk
for Hodgkin’s lymphoma (SIR Z 5.0; 95% CI 3.4e7.1). In
subsequent years of follow-up, the SIR for both immune-
related cancers and hematological cancers was 1.1
(1.0e1.1).
The SIRs for other cancers are also shown in Tables S1
and S2.
Discussion
In our cohort of more than 236,000 patients followed after
an initial hospital contact with COPD, cancer risk was
clearly higher than among the general Danish population of
comparable age. In addition to lung and other tobacco-
related cancers, we also found a high relative risk of
alcohol- and immune-related cancers, hematological
Table 1 Standardized incidence ratio for subsequent diagnosis of any cancer among 236,494 individuals with a first incident hospital contact (hospitalization or outpatient
visit) with COPD according to sex, age, year of diagnosis, and in-/outpatient status.
All cancer Number of
patients
with COPD
Within first year Within subsequent years
Number of
cancers
observed
Person-years
of follow-up
Number
of cancers
expected
Incidence rate
per 100,000
person years
Standardized
incidence
ratio (95% CI)
Number of
cancers
observed
Person-years
of follow-up
Number
of cancers
expected
Incidence rate
per 100,000
person years
Standardized
incidence
ratio (95% CI)
Overall
All patients 236,494 9434 198,584.8 3060.6 4751 3.1 (3.0e3.2) 22,759 975,255.7 15,847.0 2334 1.4 (1.4e1.5)
Sex
Women 107,150 3488 92,166.2 1183.6 3784 3.0 (2.9e3.1) 9470 469,371.6 6398.8 2018 1.5 (1.5e1.5)
Men 129,344 5946 106,418.6 1877.0 5587 3.2 (3.1e3.3) 13,289 505,884.0 9448.2 2627 1.4 (1.4e1.4)
Age (yrs)
40e49 14,646 174 13,918.5 41.6 1250 4.2 (3.6e4.9) 1172 116,884.6 707.2 1003 1.7 (1.6e1.8)
50e69 102,733 3781 91,611.6 990.0 4127 3.8 (3.7e3.9) 12,385 545,196.7 8059.6 2272 1.5 (1.5e1.6)
70þ 119,115 5479 93,054.7 2029.0 5888 2.7 (2.6e2.8) 9202 313,174.4 7080.2 2938 1.3 (1.3e1.3)
Year of diagnosis
1980e1984 34,545 1614 28,538.3 410.2 5656 3.9 (3.7e4.1) 4612 199,371.4 3191.0 2313 1.4 (1.4e1.5)
1985e1989 31,587 1417 25,894.4 394.0 5472 3.6 (3.4e3.8) 3806 162,997.1 2684.3 2335 1.4 (1.4e1.5)
1990e1994 34,616 1353 29,126.8 443.8 4645 3.1 (2.9e3.2) 4125 173,186.7 2838.9 2382 1.5 (1.4e1.5)
1995e1999 46,584 1616 40,718.5 620.2 3969 2.6 (2.5e2.7) 5348 233,503.5 3728.7 2290 1.4 (1.4e1.5)
2000e2004 50,635 1987 44,362.3 701.1 4479 2.8 (2.7e3.0) 4102 172,523.7 2848.0 2378 1.4 (1.4e1.5)
2005e2008 38,527 1447 29,944.5 491.4 4832 2.9 (2.8e3.1) 766 33,673.3 556.1 2275 1.4 (1.3e1.5)
Patient type
Outpatients 52,239 1557 48,541.3 647.7 3208 2.4 (2.3e2.5) 4993 235,451.1 3387.4 2121 1.5 (1.4e1.5)
Inpatients 184,255 7877 150,043.5 2412.9 5250 3.3 (3.2e3.3) 17,766 739,804.5 12,459.6 2401 1.4 (1.4e1.5)
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Table 2 Standardized incidence ratios (SIRs) for cancer among COPD patients with and without an alcoholism-related diag-
nosis before the time of their first hospital contact with COPD.
Cancer grouping
Alcoholism-related diagnosis
present (n Z 15,274)
Alcoholism-related diagnosis
absent (n Z 221,220)
Observed SIR (95% CI) Observed SIR (95% CI)
Any cancer
Follow-up 0e12 months 538 3.9 (3.6e4.2) 8896 3.0 (3.0e3.1)
Follow-up >12 months 1338 2.1 (2.0e2.2) 21,421 1.4 (1.4e1.4)
Tobacco-related cancers
Follow-up 0e12 months 390 7.4 (6.7e8.2) 5320 5.0 (4.9e5.1)
Follow-up >12 months 822 3.5 (3.2e3.7) 10,698 2.0 (2.0e2.0)
Non-tobacco-related cancers
Follow-up 0e12 months 148 1.7 (1.5e2.0) 3576 1.9 (1.9e2.0)
Follow-up >12 months 516 1.3 (1.2e1.4) 10,723 1.1 (1.1e1.1)
Alcohol-related cancers
Follow-up 0e12 months 123 3.1 (2.6e3.7) 1420 1.6 (1.6e1.7)
Follow-up >12 months 389 2.1 (1.9e2.4) 5202 1.1 (1.1e1.2)
Immuneerelated cancers
Follow-up 0e12 months 40 3.6 (2.6e4.9) 373 1.8 (1.6e2.0)
Follow-up >12 months 78 1.6 (1.2e1.9) 1125 1.0 (1.0e1.1)
Hematological cancers
Follow-up 0e12 months 16 1.6 (0.9e2.6) 569 2.8 (2.5e3.0)
Follow-up >12 months 47 1.0 (0.8e1.4) 1139 1.1 (1.0e1.1)
Alcoholism-related diagnoses include mental or behavioural disorders due to alcohol use, and alcoholic organ damage, see text.
COPD and cancer risk 849cancers, and cancers of the pleura, tonsil, small intestine,
thyroid gland, retroperitoneum, and peritoneum. A 40%
increased risk for cancer of any sites persisted after the
first year of follow-up, with COPD continuing to be a strong
predictor for tobacco-related cancers.
Our estimates agree with previous observations of high
risk of in particular lung cancer in COPD. In the Swedish
study of 176,997 male construction workers, those with
moderate/severe COPD had a 2.2-fold (95% CI: 1.8e2.7)
increased risk of lung cancer and a 1.6-fold (95% CI 1.4e2.0)
increased risk of extrapulmonary tobacco-related cancers
compared with men with normal lung function.12 Mild COPD
was associated with a 1.5-fold (95% CI: 1.2e1.9) increased
risk of lung cancer, but not with non-lung tobacco-related
cancer or other cancers. Similarly, an earlier Danish study
reported a “dose-response” relationship between COPD
severity and lung cancer, with a particular high risk if
patients reported chronic mucus hypersecretion, a sign of
on-going inflammation in the large airways.14 A recent
Dutch cohort mortality study found that COPD was associ-
ated with increased lung cancer mortality (hazard
ratio Z 2.1; 95% CI: 1.3e3.2) and extrapulmonary cancer
mortality (hazard ratio Z 1.4; 95% CI: 1.1e1.9) in a cohort
of 3371 patients with peripheral arterial disease who
underwent vascular surgery.15 A Dutch cross-sectional study
of 73,255 newly diagnosed cancer patients found that 12%
of patients had COPD at the time of diagnosis,28 while up to
50% of patients with lung cancer reportedly have spiro-
metric evidence of COPD.29Several mechanisms may underlie the observed associ-
ation between hospital-diagnosed COPD and cancer.
Heightened diagnostic surveillance and presence of undi-
agnosed cancer at the time of the first COPD hospital
contact may explain much of the strong short-term asso-
ciation, but is less likely to explain the markedly increased
cancer risk in subsequent years. Initial false diagnosis of
COPD might also partly explain the high early rates of lung
cancer diagnoses, but such misclassification is unlikely to
explain the highly increased lung cancer risk after 5e10
years of follow-up. The observed high SIR for lymphomas
during the first year of follow-up is probably due to diag-
nostic bias, since the SIR was 1 in following years.
A plausible explanation for the association between
hospital-diagnosed COPD and cancer is the sharing of risk
factors like smoking, poor diet, low level of physical
activity, and high alcohol consumption. Smoking is the
predominant risk factor for COPD and an important risk
factor for pulmonary but also other cancer, potentially
caused by circulating systemic tobacco carcinogens. Among
11,580 COPD patients seen at hospital outpatient clinics in
Denmark during 2010, 32% reported to be current smokers
and 65% were former smokers (unpublished data).30 Thus,
we believe smoking may explain much of the observed long-
term cancer risk increase associated with COPD. However,
local lung inflammation per se may predispose to lung
cancer,10,12,14,15 consistent with a very high incidence of
lung cancer in patients with idiopathic pulmonary fibrosis.31
Unfortunately, we lacked the data necessary to examine
Table 3 Standardized incidence ratios (SIRs) for cancer among COPD patients with different levels of comorbidity before the
time of their first hospital contact with COPD.
Cancer grouping Low comorbidity
(n Z 149,995)
Medium comorbidity
(n Z 74,196)
High comorbidity
(n Z 12,303)
Observed SIR (95% CI) Observed SIR (95% CI) Observed SIR (95% CI)
All cancers
Follow-up 0e12 months 6344 3.3 (3.2e3.4) 2671 2.7 (2.6e2.8) 419 2.6 (2.4e2.9)
Follow-up >12 months 16,243 1.4 (1.4e1.5) 5894 1.5 (1.4e1.5) 622 1.6 (1.5e1.7)
Tobacco-related cancers
Follow-up 0e12 months 3894 5.5 (5.3e5.7) 1587 4.5 (4.2e4.7) 229 4.1 (3.5e4.6)
Follow-up >12 months 8233 2.0 (2.0e2.1) 2961 2.1 (2.0e2.2) 326 2.4 (2.1e2.7)
Non-tobacco-related cancers
Follow-up 0e12 months 2450 2.0 (2.0e2.1) 1084 1.7 (1.6e1.8) 190 1.9 (1.6e2.2)
Follow-up >12 months 8010 1.1 (1.1e1.1) 2933 1.1 (1.1e1.2) 296 1.2 (1.0e1.3)
Alcohol-related cancers
Follow-up 0e12 months 999 1.8 (1.7e1.9) 460 1.6 (1.4e1.7) 84 1.8 (1.5e2.3)
Follow-up >12 months 3928 1.1 (1.1e1.2) 1507 1.2 (1.2e1.3) 156 1.4 (1.2e1.6)
Immuneerelated cancers
Follow-up 0e12 months 250 1.8 (1.6e2.1) 130 1.8 (1.5e2.2) 33 2.9 (2.0e4.1)
Follow-up >12 months 845 1.0 (1.0e1.1) 308 1.0 (0.9e1.2) 50 1.8 (1.3e2.3)
Hematological cancers
Follow-up 0e12 months 391 2.9 (2.6e3.2) 175 2.5 (2.1e2.9) 19 1.6 (1.0e2.6)
Follow-up >12 months 841 1.0 (1.0e1.1) 312 1.1 (1.0e1.2) 33 1.2 (0.8e1.6)
Level of comorbidity categorized as low (Charlson comorbidity index score of 0), medium (score of 1e2), and high (score of 3), see
text.
850 J.B. Kornum et al.the role of smoking in our study. Confounding by alcohol
overuse may also affect the observed association between
COPD and certain tobacco-related cancers, such as cancer
of the oral cavity, pharynx, larynx, esophagus, and liver.
However, we observed a twofold increased long-term risk
of tobacco-related cancers even among COPD patients
without an alcohol-related diagnosis.
Other comorbidities might partially explain the
increased cancer risk associated with hospital-diagnosed
COPD, but we observed a 40% increased long-term risk evenTable 4 Absolute risks for cancer in 236,494 individuals with a
No. cancers
observed
within first year
1-year cancer
risk in percent
(95% CI)
No.
obs
wit
5 ye
Any cancer 9434 4.0%
(4.0e4.1%)
21,
Lung cancer 4209 1.8%
(1.7e1.9%)
8
Tobacco-related
cancers other than
lung cancer
1501 0.6%
(0.6e0.7%)
3
Alcohol-related cancers 1543 0.7%
(0.6e0.7%)
4in COPD patients without any previously recorded comor-
bidity. In recent years there has been substantial interest in
the low-grade systemic inflammation associated with
COPD17,32,33 and an increased risk of cancer has been
mentioned as a possible consequence of this systemic
inflammatory process.17 It is also possible that genetic
differences in inflammatory responses may contribute to
both COPD and cancer development.
The strengths of our study include its long and complete
follow-up, the non-differential ascertainment of outcomesfirst incident hospital contact with COPD.
cancers
erved
hin first
ars
5-year cancer
risk in percent
(95% CI)
No. cancers
observed within
first 10 years
10-year cancer
risk in percent
(95% CI)
615 9.9%
(9.8e10.0%)
28,456 14.2%
(14.1e14.4%)
051 3.6%
(3.6e3.7%)
10,118 4.9%
(4.9e5.0%)
994 1.8%
(1.8e1.9%)
5327 2.7%
(2.6e2.8%)
438 2.1%
(2.0e2.1%)
6167 3.2%
(3.1e3.2%)
Figure 1 Standardized incidence ratio for diagnosis of any cancer among individuals with a first incident hospital contact with
COPD.
COPD and cancer risk 851through population-based registries, the ability to examine
cancer incidence rather than mortality, and the large
sample size conferring relatively high statistical precision.
Some coding errors may have occurred, but the positive
predictive value of a hospital diagnosis of COPD (J44.x) in
Denmark is 92% (95% CI: 91e93%), assessed based on medical
history, clinical symptoms and findings, and spirometry
results.30 Another limitation was the lack of data on smoking
and other lifestyle factors associated with both COPD and
cancer risk, and the lack of data on the severity of COPD.12
Since our patients were recruited exclusively in the
hospital setting, the vast majority were likely to have severe
or very severe COPD.30 Based on recent population
surveys,3,6 Denmark (population 5.5 million) has an esti-
mated COPD prevalence of 450.000 (8% of the total pop-
ulation, or approximately 15% among adults aged 40þ years)
and Danish hospitals admitted 13.000 patients with a new
first-time hospitalization with COPD in 2006.34
In conclusion, patients with newly hospital-diagnosed
COPD are at considerably increased risk of developing lung
cancer and cancers at other sites. The pattern of cancer
sites indicates that much of the overall increased cancer
risk is attributable to smoking. Since improvements in
treatment are increasing the longevity of COPD patients,
the cancer burden is likely to increase among this patient
group. Further research is needed to determine whether
the observed increased risk justifies a special surveillance
program or a more active case-finding approach by treating
physicians.
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